Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Treatment Results With Dasatinib Or Nilotinib In Third Line Therapy Of Chronic Myeloid Leukemia After Failure Of Two Tyrosine Kinase Inhibitors

Beatriz F Ribeiro, Eliana C M Miranda, MEd, Marcia T Delamain, MD, Gislaine Borba Oliveira, MD,, Maria Helena Almeida, RN, Vagner O Duarte, Irene L Metze, MD, PhD, Carmino A De Souza, Sr., MD, PhD, Rosana A Silveira, Katia B. Pagnano, MD, PhD

Blood (2013) 122 (21): 5189.

https://doi.org/10.1182/blood.V122.21.5189.5189

Published: 2013

Journal Articles

Early Molecular Response Is Predictive Of Overall, Progression-Free and Event-Free Survival In Chronic Myeloid Leukemia Using Second-Generation Tyrosine Kinase Inhibitors After Imatinib Treatment

Beatriz F Ribeiro, Bruna Vergilio, Eliana C M Miranda, MEd, Maria Helena Almeida, RN, Marcia Torresan Delamain, MD, Rosana A Silveira, MSc, Carmino A De Souza, Sr., MD, PhD, Dulcinéia Martins Albuquerque, BSc, MSc, PhD, Andrey dos Santos, PhD, Irene Lorand-Metze, MD, PhD, Vagner O Duarte, Gislaine O. Duarte, PhD, Katia B. Pagnano, MD, PhD

Blood (2013) 122 (21): 1326.

https://doi.org/10.1182/blood.V122.21.1326.1326

Published: 2013

Journal Articles

Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitors– A Study on Behalf of Latin American Leukemia Net (Lalnet)

Blood (2011) 118 (21): 1701.

https://doi.org/10.1182/blood.V118.21.1701.1701

Published: 2011

Journal Articles

Gene Expression Profile in Responsive and Non-Responsive Chronic Myeloid Leukemia Patients Treated with Dasatinib.

Rosana A Silveira, MSc, Angela A Fachel, Yuri B Moreira, Marcia T Delamain, MD, Carmino Antonio De Souza, MD, PhD, Fernando Ferreira Costa, Ph.D., M.D., Sergio Verjovski-Almeida, MD, PhD, Katia B.B. Pagnano, MD, PhD

Blood (2009) 114 (22): 3260.

https://doi.org/10.1182/blood.V114.22.3260.3260

Published: 2009

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia with T315I BCR-ABL Mutation

Kati a BB Pagnano, MD, PhD, Rosana A Silveira, Luciana Nardinelli, Monika Conchon, MD, PhD, Carmino De Souza, MD, PhD, Pedro ED Llacer, MD, Phd, Irene Lorand-Metze, MD, PhD, Vaneuza Funke, MD, Ricardo Pasquini, MD, PhD, Cintia C Mascarenhas, Maria Aparecida Zanichelli, MD, Phd, Nelma CD Clementino, MD, PhD, Israel Bendit, MD, PhD

Blood (2008) 112 (11): 4262.

https://doi.org/10.1182/blood.V112.11.4262.4262

Published: 2008

Journal Articles

Screening of Mutations in BCR-ABL Kinase Domain in Chronic Myeloid Leukemia (CML) Patients Treated with Kinase Inhibitors by Denaturing High-Performance Liquid Chromatography (D-HPLC).

Cintia C. Mascarenhas, Anderson F. Cunha, Katia B.B. Pagnano, MD, Rosana A. Silveira, Fernando F. Costa, MDPhD, Ricardo Pasquini, MDPhD, Nelma C.D. Clementino, MDPhD, Carmino A. De Souza, MDPhD

Blood (2007) 110 (11): 4580.

https://doi.org/10.1182/blood.V110.11.4580.4580

Published: 2007

Journal Articles

Detection of BCR-ABL Point Mutations in Patients with Chronic Myeloid Leukemia (CML) Resistant to Imatinib.

Rosana A. Silveira, Dulcineia M. Albuquerque, PhD, Angela M. Assis, Edson Ichihara, Carmino A. de Souza, MD,PhD, Fernando F. Costa, MD,PhD, Marcia T. Delamain, MD, Afonso C. Vigorito, MD,PhD, Irene Lorand-Metze, MD,PhD, Eliana Miranda, Katia B.B. Pagnano, MD,PhD

Blood (2006) 108 (11): 4817.

https://doi.org/10.1182/blood.V108.11.4817.4817

Published: 2006

NARROW

Treatment Results With Dasatinib Or Nilotinib In Third Line Therapy Of Chronic Myeloid Leukemia After Failure Of Two Tyrosine Kinase Inhibitors

Early Molecular Response Is Predictive Of Overall, Progression-Free and Event-Free Survival In Chronic Myeloid Leukemia Using Second-Generation Tyrosine Kinase Inhibitors After Imatinib Treatment

Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitors– A Study on Behalf of Latin American Leukemia Net (Lalnet)

Gene Expression Profile in Responsive and Non-Responsive Chronic Myeloid Leukemia Patients Treated with Dasatinib.

Outcome of Patients with Chronic Myeloid Leukemia with T315I BCR-ABL Mutation

Screening of Mutations in BCR-ABL Kinase Domain in Chronic Myeloid Leukemia (CML) Patients Treated with Kinase Inhibitors by Denaturing High-Performance Liquid Chromatography (D-HPLC).

Detection of BCR-ABL Point Mutations in Patients with Chronic Myeloid Leukemia (CML) Resistant to Imatinib.

Email alerts

ASH Publications

American Society of Hematology

Treatment Results With Dasatinib Or Nilotinib In Third Line Therapy Of Chronic Myeloid Leukemia After Failure Of Two Tyrosine Kinase Inhibitors

Early Molecular Response Is Predictive Of Overall, Progression-Free and Event-Free Survival In Chronic Myeloid Leukemia Using Second-Generation Tyrosine Kinase Inhibitors After Imatinib Treatment

Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitors– A Study on Behalf of Latin American Leukemia Net (Lalnet)

Gene Expression Profile in Responsive and Non-Responsive Chronic Myeloid Leukemia Patients Treated with Dasatinib.

Outcome of Patients with Chronic Myeloid Leukemia with T315I BCR-ABL Mutation

Screening of Mutations in BCR-ABL Kinase Domain in Chronic Myeloid Leukemia (CML) Patients Treated with Kinase Inhibitors by Denaturing High-Performance Liquid Chromatography (D-HPLC).

Detection of BCR-ABL Point Mutations in Patients with Chronic Myeloid Leukemia (CML) Resistant to Imatinib.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only